| Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. | |
| | |
MedLine Citation:
|
PMID: 20973683 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
STUDY OBJECTIVE: To assess the contribution of polymorphisms in the uridine diphosphate glucuronosyltransferase gene (UGT) and the multidrug resistance-associated protein 2 gene (ABCC2) to mycophenolic acid (MPA) pharmacokinetics and clinical outcomes in thoracic transplant recipients. DESIGN: Open-label, cross-sectional study. SETTING: Transplant clinic in Vancouver, British Columbia, Canada. PATIENTS: Sixty-eight thoracic (36 lung, 32 heart) transplant recipients who were receiving steady-state oral mycophenolate mofetil. MEASUREMENTS AND MAIN RESULTS: Eleven blood samples were obtained from each patient over a 12-hour dosing period. Plasma concentrations of MPA (active metabolite of mycophenolate mofetil), the MPA metabolites 7-Omycophenolic acid glucuronide (MPAG) and acyl glucuronide (AcMPAG), and free MPA were measured, and dose-normalized conventional pharmacokinetic parameters were determined by noncompartmental methods. Genetic polymorphisms in UGT and ABCC2 were determined by sequencing, and their contributions to pharmacokinetic variability were investigated by using multivariate analysis. For both the lung and heart transplant groups, the UGT2B7 variant 802T (Tyr(268) or UGT2B7*2, rs7439366) and the UGT2B7 variant -138A modified AcMPAG exposure (2.5-3.7-fold and 9.3-12.3-fold higher AcMPAG area under the concentration-time curve [AUC] and AcMPAG:MPA ratio, respectively). In an exploratory analysis, occurrences of rejection, infection, anemia, and leukopenia were associated with an AcMPAG AUC greater than 50 μg·hour/ml and an AcMPAG:MPA ratio greater than 2. CONCLUSION: UGT2B7 is a promising gene candidate that may influence MPA pharmacokinetics clinically; however, larger clinical pharmacogenetic studies in thoracic transplant subpopulations are warranted to corroborate the role of AcMPAG and UGT2B7 variants in optimizing mycophenolate mofetil therapy. |
| | |
Authors:
|
Lillian S L Ting; Marie-Odile Benoit-Biancamano; Olivier Bernard; K Wayne Riggs; Chantal Guillemette; Mary H H Ensom |
Related Documents
:
|
14723603 - Mycophenolate mofetil treatment following renal transplantation decreases gtp concentra... 9075853 - Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year dat... 16041263 - Lymphoproliferative disease after renal transplantation in australia and new zealand. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Pharmacotherapy Volume: 30 ISSN: 1875-9114 ISO Abbreviation: Pharmacotherapy Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-26 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 1097-108 Citation Subset: IM |
Affiliation:
|
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Grant Support | |
ID/Acronym/Agency:
|
MOP-133946//Canadian Institutes of Health Research |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurolog...
Next Document: Suboptimal use of inhaled corticosteroids in children with persistent asthma: inadequate prescriptio...